Lettuce-Based Oral GLP-1 Agonists Show Promise for Diabetes and Obesity Treatment

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective in treating type 2 diabetes and obesity. However, these medications face significant challenges related to manufacturing cost, complex delivery systems, and potential side effects, particularly in low- and middle-income countries. These agonists stimulate insulin release, suppress glucagon, control blood sugar, reduce appetite, and delay gastric emptying.

A new study led by Henry Daniell of the University of Pennsylvania's School of Dental Medicine investigates an oral delivery method for exenatide and lixisenatide, two established GLP-1 receptor agonists. The research, published in Plant Biotechnology Journal, indicates that genetically engineered lettuce chloroplasts can produce functional GLP-1 peptides.

Overcoming Oral Delivery Challenges

Oral delivery of peptides typically encounters issues with digestion in the stomach and poor absorption in the gut. The study's novel approach utilizes plant encapsulation to protect the peptides from stomach degradation and facilitate gut absorption. Researchers selected exenatide and lixisenatide due to their established clinical use and safety records.

"The study's approach utilizes plant encapsulation to protect the peptides from stomach degradation and facilitate gut absorption."

Innovative Plant-Based Mechanism

Incorporating GLP-1 therapies into the lettuce genome avoids synthesis challenges common in conventional oral formulations, such as the need to adjust stomach acid pH. Plant cells are resistant to human digestion, but gut bacteria break down their cell walls, releasing the therapeutic peptides. This method also allows chloroplasts to naturally perform post-translational modifications required for peptide function.

Potential Benefits: Safety and Cost Reduction

Using natural versions of these peptides, as opposed to synthetic forms with artificial amino acids, may reduce the risk of gastrointestinal side effects observed with some current GLP-1 drugs. Additionally, simplifying the production process by using plant cells is expected to lower overall manufacturing costs.

"Simplifying the production process by using plant cells is expected to lower overall manufacturing costs."

Next Steps Towards Clinical Application

Daniell and his team are currently focused on scaling up the production of these plant-encapsulated GLP-1 receptor agonists. Their plans include preparing for early-stage clinical trials to further evaluate this promising new treatment method.